SCHEMBL15941016

SCHEMBL15941016

NCc1ccc(-c2ccco2)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 1/20 0.56
▸ CYP11B1 P15538 1/20 0.56
▸ CYP11B2 P19099 1/20 0.56
▸ MAPT P10636 5/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ ALDH1A1 P00352 8/20 0.41
▸ KDM4E B2RXH2 5/20 0.41
▸ BLM P54132 4/20 0.41
▸ RAB9A P51151 7/20 0.40
▸ NPC1 O15118 6/20 0.40
▸ SMN1; SMN2 Q16637 5/20 0.40
▸ POLB P06746 5/20 0.40
▸ TP53 P04637 1/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ ECE1 P42892 1/20 0.39
▸ USP2 O75604 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16880660 0.83 CYP11B1 (0.56) TAAR1CYP11B1CYP11B2MAPTHSD17B10
SCHEMBL30183025 0.79 CYP11B1 (0.52) CYP11B1CYP11B2MAPTHSD17B10ALDH1A1
SCHEMBL351473 0.77 LOXL2 (0.46) TAAR1CYP11B1CYP11B2CYP2A6
SCHEMBL17730334 0.77 TAAR1 (0.52) TAAR1CYP11B1CYP11B2MAPTHSD17B10
SCHEMBL7016885 0.76 TAAR1 (0.51) TAAR1CYP11B1CYP11B2MAPTHSD17B10
SCHEMBL26673591 0.76 TAAR1 (0.43) TAAR1CYP11B1CYP11B2MAPTHSD17B10
SCHEMBL31064975 0.75 ALDH1A1 (0.52) CYP11B1CYP11B2MAPTHSD17B10ALDH1A1
SCHEMBL14714583 0.74 CYP11B1 (0.45) CYP11B1CYP11B2MAPTALDH1A1KDM4E
SCHEMBL14973812 0.74 CYP11B1 (0.47) CYP11B1CYP11B2MAPTHSD17B10ALDH1A1
SCHEMBL15013249 0.73 CYP11B1 (0.44) CYP11B1CYP11B2MAPTHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2953951-B1 N2-SUBSTITUTED-N6-(6-ARYL-PYRIDINE-3-YLMETHYL)-9-CYCLOPENTYL-9H-PURINE-2,6-DIAMINE DERIVATIVES AS TUMOR SUPPRESSOR P53 ACTIVATORS FOR INHIBITING ANGIOGENESIS AND FOR TREATING CANCER UNIV PALACKEHO (CZ) 2017-05-03 — — EP disclosed
US-20150368248-A1 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS BIOPATTERNS S.R.O. (CZ) 2015-12-24 — — US disclosed
EP-2953951-A2 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS Univerzita palackeho V Olomouci (CZ) 2015-12-16 — — EP disclosed
WO-2014121764-A2 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2014-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368248-A1 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS ENTPD5, PNP, HCCS TAAR1 3240/4885CYP11B1 380/4885CYP11B2 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback